Maxcyte (MXCT) Equity Average (2020 - 2026)

Maxcyte (MXCT) has 7 years of Equity Average data on file, last reported at $169.7 million in Q1 2026.

• Quarterly Equity Average fell 16.34% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.7 million (down 16.34% YoY) and the FY2025 annual result came in at $188.9 million, down 13.84% from the prior year.
• Equity Average slipped to $169.7 million in Q1 2026 per MXCT's latest filing, from $175.9 million in the prior quarter.
• Across five years, Equity Average topped out at $262.5 million in Q1 2022 and bottomed at $169.7 million in Q1 2026.
• The 5-year median for Equity Average is $229.3 million (2024), against an average of $223.9 million.
• The widest annual swing landed in 2022, when Equity Average surged 358.54%; it then slipped 16.34% in 2026.
• Tracing MXCT's Equity Average over 5 years: stood at $254.2 million in 2022, then dropped by 8.43% to $232.8 million in 2023, then declined by 9.88% to $209.8 million in 2024, then declined by 16.16% to $175.9 million in 2025, then declined by 3.52% to $169.7 million in 2026.
• Per Business Quant, the three latest MXCT Equity Average figures stand at $169.7 million (Q1 2026), $175.9 million (Q4 2025), and $185.5 million (Q3 2025).

Peer Comparison